Risperidone Depot (Microspheres) in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder - an Open Label Follow up Trial of RIS-INT-57 and RIS-INT-61.
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2010
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Sponsors Janssen
- 07 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2007 New trial record.